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BRONCHIOLITIS OBLITERANS SYNDROME FOLLOWING ALLOGENEIC
HEMATOPOIETIC CELL TRANSPLANTATION: PREVALENCE, RISK FAC-
TORS, AND OUTCOMES
Au, B.K.C., Au, M.A., Chien, J.W. Fred Hutchinson Cancer Research
Center, Seattle, WA
We conducted a retrospective cohort study of the prevalence, risk
factors and outcomes of bronchiolitis obliterans syndrome (BOS),
a serious late pulmonary complication of allogeneic hematopoietic
cell transplantation (aHCT).
Methods: Pulmonary function tests (PFTs) from 1145 patients who
received their first aHCT between January 1, 2002 and June 30,
2006 were screened at$ 1 year after aHCT to identify patients who
met the NIH spirometry criteria for BOS (FEV1# 75% and FEV1/
VC ratio\0.7) and had a$ 10% decline in FEV1 compared to pre-
transplant values. Clinical, microbiologic, and radiologic records
were reviewed to exclude pulmonary infection and other causes of air-
flow obstruction as well as record supportive evidence for BOS.
Results: The overall prevalence of BOS among all transplanted pa-
tients was 5.5%. The prevalence of BOS among patients with chronic
graft-versus-host disease (cGVHD) and patients surviving to at least 1
year were 16% and 10%, respectively. The median time from trans-
plant to meeting spirometric criteria for BOS was 439 days (range
274-1690). 60% of the 63 total cases were clinically recognized at
the time of meeting NIH criteria, 23% were recognized
aftermeetingNIHcriteria, and 17%were never clinically recognized.
At the time of meeting NIH spirometric criteria, 95% of cases had
concurrent evidence of air trapping onPFTs (n5 58) and/or support-
ive evidence of BOS on high-resolution chest CT (n5 25). BOS was
significantly associated with cGVHD (p\0.001), low baseline FEV1
(p5 0.035), and low baseline FEV1/VC ratio (p5 0.001), but not
with other previously identified risk factors such as busulfan-based
regimen, peripheral blood stem cell source, donor-recipient gender
mismatch, or acuteGVHD. 48%of BOSpatients were on an immune
taper within 3months prior tomeetingNIH criteria. Survival analysis
revealed a significant difference inKaplanMeier survival estimates be-
tween subjects with and without BOS (p5 0.002). Non-relapse sur-
vival differed significantly based on clinical recognition status at the
time of meeting spirometric criteria (p5 0.027), with concurrently-
recognized patients having the worst survival.
Conclusion:These results suggest that BOSmay be more prevalent
than previously thought. Frequent assessment of high-risk patients
with cGVHD may help with earlier detection and intervention for
this often-fatal disease.8
PROSPECTIVE COMPARISON OF REDUCED INTENSITY (FLU-BU-ATG) VS.
NON-MYELOABLATIVE (FLU-TBI) CONDITIONING FOR MATCHED RE-
LATED ALLO-SCT: A CLINICAL AND COST-EFFECTIVENESS MULTICENTER
ITAC STUDY (MINI VS. MICRO TRIAL)
Blaise, D.1, Tabrizi, R.2, Le Corroller, A.G.1, Michallet, M.3, Bay, J.O.4,
Mohty, M.1, Faucher, C.1, Milpied, N.2, Castagna, L.1, Boyer
Chammard, A.1, Boher, J.M.1 1 Institut Paoli-Calmettes, Marseille,
France; 2CHUHaut Leveque, Pessac, France; 3Hopital Edouard Herriot,
Lyon, France; 4Centre Jean Perrin, Clermont Ferrand, France
We prospectively compare 2 RIC: FBA (Fluda (150 mg/m2)+Oral
Bu (8 mg/kg) +Thymoglobuline (2.5 mg/kg)) (IS: CSA) or FTBI
(Fluda (90 mg/m2)+2 Gy TBI) (IS: CSA +MMF). Inclusion criteria:
hematological malignancies, pts non eligible for myeloablative CDT,
age between 18 and 65, HLA identical sibling. Groups (FBA:
N5 69; FTBI: N5 70) were comparable: age 54 (21-65); Male:
65%; Diag: AL 18%; NHL 23%; MM 39% others 20%; status: CR:
32%; SD5 60%; REF5 8%). Graft failure occured in 4 pts (6%) in
FTBI. Cumulative incidences (CI) of grade .5 2 aGVHD andcGVHD were respectively: 37% (FBA 51%; FTBI 26%; p5 .003)
and 77% (FBA 79%; FTBI 76%: p5NS). At 1 year, PFS differed
(FBA 0.68 [0.56 – 0.78]; FTBI 0.51 [0.39 – 0.62]; p5 0.048) while
OS was similar (FBA 0.75 [0.63 – 0.84]; FTBI 0.74 [0.62 – 0.83];
p5NS). With a f.up of 39 months (3-71), 72 pts were alive (FBA:
35; FTBI: 37: p5NS) for a 5 year probability of 0.45 [0.31– 0.57]
and 0.49 [0.35– 0.61] for FBA and FTBI respectively (p5NS). 5
year PFS probability were 0.35 [0.22– 0.48] for FBA and 0.23 [0.10–
0.38] for FTBI (p5NS). Median PFS were 26.3 (IC95%:13.6 –
47.3) and 13.1 (IC95%:7.4 – 25.6)months (mths) in FBA andFTBI re-
spectively.More relapses/progressions occurred in FTBI (p5 .005): 5
year relapse/progression CI of 0.28 [0.16– 0.40] (FBA) and 0.50 [0.39–
0.60] (FTBI). 3 pts died from secondary cancers (FBA: 1; FTBI: 2) and
38 fromTRMwith a 5 year TRMCI of 0.37 [0.25– 0.49] for FBA and
0.24 [0.14– 0.34] for FTBI (p5 0.199). FBA had a stronger negative
impact on patients’ QOL up to 80 days and resolved (EORTC
QLQ-C30 questionnaire). Evaluation of medical direct costs demon-
strated a crude advantage for FTBI (66,711V vs 42,080V for the
FBA and FTBI respectively, p\0.001). The cost-effectiveness ratio
using PFS as endpoint was 22,392 V per year of life free of relapse
gained using FBA conditioning regimen when compared to FTBI. In
conclusion, these 2 regimens produce similar 1 year OS. However,
FBA is associated with better 1 year PFS and socially acceptable cost-
effectiveness ratio but worse early QOL. FBA is also associated with
better long termdisease control, whereas FTBI tends toproduce lower
TRM and higher rejection rates.9
TNF-INHIBITIONWITH ETANERCEPT FOR GVHD PREVENTION IN ALTER-
NATIVE DONOR HCT: LOWER TNFR1 LEVELS CORRELATE WITH BETTER
OUTCOMES
Choi, S.W.1, Stiff, P.2, Braun, T.1, Ferrara, J.L.M.1, Cooke, K.3,
Khaled, Y.1, Kitko, C.1, Lay-Luskin, J.1, Mineishi, S.1, Nickoloff, B.2,
Paczesny, S.1, Pawarode, A.1, Peres, E.1, Reddy, P.1, Richardson, J.1,
Rodriguez, T.2, Smith, S.2, Yanik, G.1, Whitfield, J.1, Levine, J.E.1
1University of Michigan, Ann Arbor, MI; 2Loyola University Medical
Center, Chicago, IL; 3Case Western Reserve University School of Medi-
cine, Cleveland, OH
TNF Receptor 1 (TNFR1) levels have previously been shown to
predict GVHD, non-relapse mortality (NRM) and overall survival.
We therefore conducted a phase II trial at two centers between
2005 and 2009 using the TNF-inhibitor etanercept together
with standard tacrolimus/methotrexate in high-risk allogeneic
matched unrelated donor (URD) (n5 68), single antigen mis-
matched URD (n5 25), or single antigen mismatched related donor
(n5 3) hematopoietic cell transplant (HCT) recipients. The median
age was 45y (range 2-61y). Patients received etanercept (0.4 mg/kg,
max 25 mg) twice weekly from the start of conditioning to day 56
in addition to tacrolimus and methotrexate (5 mg/m2 on days 1, 3,
6, and 11). The myeloablative conditioning regimens included flu-
darabine and IV busulfan 12.8 mg/kg (FluBu4, n5 31), BCNU/eto-
poside/cyclophosphamide or busulfan/cyclophosphamide (BCNU/
Busulfan, n5 36), and TBI/cyclophosphamide (TBI, n5 29).
We hypothesized that the administration of the TNF-inhibitor
etanercept would lower TNFR1 levels, and thereby protect
against GVHD and NRM while improving survival. The median
day 7 TNFR1 level was 2518 pg/mL in study patients, signifi-
cantly lower than the 3529 pg/mL seen in 132 control patients
(p\0.001) matched for age, conditioning regimen, degree of
HLA-match, and disease status. We then examined whether day
7 TNFR1 levels were associated with outcomes in study patients
and found an increased risk for NRM (HR 2.0, p\0.001) and
death (HR 1.5, p\0.06) for each doubling of TNFR1 levels.
As shown in the Table, the day 7 TNFR1 levels differed statisti-
cally according to the myeloablative conditioning regimen
(p\0.001). FluBu4 patients experienced the lowest day 7
TNFR1 levels compared to other study patients and had the low-
est rates of grade 2-4 GVHD (39% p5 0.04), no deaths in theS157
PATIENTOUTCOMES BY CONDITIONING REGIMEN
Median Day 7
TNFR1 Levels (pg/mL)
Mean Day 7 TNFR1
Levels (pg/mL)
Day 100 Grade
2-4 GVHD
Day 100 Grade
3-4 GVHD
Day 100
NRM
2 year
NRM
2 year
OS
Overall (n5 96) 2518 3053 53% 23% 16% 34% 55%
FluBu4 (n5 31) 1735 1897 39% 11% 0% 12% 70%
BCNU/Busulfan (n5 36) 2552 3009 61% 25% 14% 31% 58%
TBI (n5 29) 3907 4226 62% 32% 34% 55% 38%
S158 Oral Presentationsfirst 100 days (p\0.001), and improved 2 year survival rates (70%
p5 0.03).
Our data suggest that etanercept effectively reduces TNFR1 levels
at day 7 post-HCT, which has previously been correlated with trans-
plant outcomes. The median day 7 TNFR1 levels were statistically
different across conditioning regimens, and those with low
TNFR1 levels had improved outcomes (FluBu4. BCNU/Busul-
fan.TBI). The combination of FluBu4 with etanercept as a prom-
ising regimen for high-risk allogeneic HCT warrants further
investigation.10
THE ROLE OF DONOR-SPECIFIC ANTI-HLA ANTIBODIES (DSA) IN HEMA-
TOPOIETIC STEM CELL TRANSPLANTATION FROM MATCHED UNRE-
LATED DONORS
Ciurea, S.O.1, Cano, P.2, de Lima, M.1, Thall, P.F.3, Rondon, G.1,
Kebriaei, P.1, Alousi, A.1, Hosing, C.1, Khouri, I.F.1, Champlin, R.E.1,
Fernandez-Vina, M.2 1The University of Texas M.D. Anderson Cancer
Center; 2The University of Texas M.D. Anderson Cancer Center; 3The
University of Texas M.D. Anderson Cancer Center, Houston, TX
We have previously identified a high risk of primary graft failure
(PGF) in patients with DSA in T-cell depleted haploidentical trans-
plantation (HaploSCT); 3/4 patients with DSA developed PGF
compared with 1/20 patients without DSA. All patients with DSA
against anti-HLA-A, -B and -DRB1 developed PGF, while 1 patient
with anti-DP DSA did not. We hypothesized that anti-DP anti-
bodies may have a significant but less deleterious impact on engraft-
ment and evaluated the occurrence of PGF in 487 patients who
received matched unrelated donor transplants (MUDT) at our insti-
tution after 9/2005. Approximately 80% of the transplants were mis-
matched in HLA-DPB1 in the HvG vector. The presence of DSA
was determined by testing the patients’ sera with a panel of fluores-
cent beads coated with single HLA antigen preparations using
a Luminex platform; results were interpreted as fluorescence
intensity (FI) against DSA mismatch as previously defined by us
(see Table Footer). HLA-A,-B,-C,-DRB1,-DRB3/4/5,-DQB1 and
-DPB1 were typed by high resolution methods. Specificity and
intensity of antibodies is described in the Table. Eight patients had
PGF, and 8 had early death. In each category one had DSA. Median
time to ANC500 was 12 days. We found that 5 patients (1%)
presented DSA in their pre-transplant specimens, all females with
a median age of 49 years, and matched with their donors in 10/10 al-
leles. In all patients the DSA were directed against HLA-DP mole-
cules with intermediate to strong intensities. One patient withNumber Anti-DP DSA
DSA
levels
before
1st SCT
Engrafted
(Y/N)
2nd
SCT
(Y/N)
DSA
levels
before
2nd SCT
Engrafted
(Y/N)
1 DPB1*03DBZB 41 N N N/A N/A
2 DPB1*0401 11 to 21 Y N N/A N/A
3 DPB1*0301 31 N Y 0 Y
4 DPA1*0201
and DPB1*0101
31 Y N N/A N/A
5 DPB1*0101 and
DPB1*1101
31 and 11 Y N N/A N/A
DSA-donor-specific anti-HLA antibodies; Y- yes, N-no; N/A- not applica-
ble; 0 - no DSA, FI\500 or negative; weak (500-1500 FI, 11), interme-
diate (1500-3000 FI, 21), strong (3000-7500 FI, 31); very strong
(.7500 FI, 41).DSA (#1) received rituximab/plasma exchange prior to transplant
to decrease DSA levels and died on day 22 without engraftment. Ex-
cluding the patients with early death, we have found a moderate as-
sociation between anti-DP antibodies and PGF (p5 0.0654). When
early death was considered as a negative event associated with DSA,
a significant association was identified between the presence of anti-
DP DSA and graft failure/early death outcome (p5 0.0108, Fisher’s
Exact Test).
Conclusions:These results, combined with our previous findings in
HaploSCT, suggest that anti-DP DSA compared with DSA against
anti-HLA-A, B or DRB1 may have a lower risk for PGF. The differ-
ences may reside in the lower levels of DP molecules expressed on
cell surface. DSA screening is warranted when considering donors
with HLA mismatches as strategies for donor selection and/or anti-
body level reduction may be needed to decrease the risk of PGF in
allogeneic HSCT from partially HLA-matched donors.11
EVALUATION OF PATIENTSWITH MYELODYSPLASTIC SYNDROME (MDS)
UP TO AGE SEVENTY-FIVE, REFERRED FOR ALLOGENEIC HEMATOPOI-
ETIC CELL TRANSPLANT (HCT) INCLUDING DONOR AVAILABILITY AND
HCT OUTCOMES
Field, T.L., Perkins, J., Kim, J., Kharfan-Dabaja,M.A., Fenandez, H.F.,
Perez, L., Lancet, J., Komrokji, R.S., Ochoa-Bayona, L., Alsina, M.,
List, A., Anasetti, C. Moffitt Cancer Center, Tampa, FL
Allogeneic HCT remains the only curative treatment strategy for
patients (pts) with MDS. Moffitt Cancer Center (MCC) has imple-
mented a targeted IV busulfan plus fludarabine (tBuFlu) induction
regimen that is myeloablative, with reduced treatment related toxic-
ity, permitting the expansion of empiric age limitations for HCT up
to 75 years (yrs). From January 2004 on, 243 new pts (NP) with a
diagnosis of MDS or CMML were evaluated for HCT. An alloge-
neic donor was identified in 170 pts and 112 received an HCT.
The median age of the 112 transplant pts was 55.6 yrs (24.8 –
73.5). Sixty pts were older than 55 yrs. At the NP visit, IPSS risk
was Low (11), Int-1 (35), Int-2 (42), and High (21) or not evaluable
(3) (NE). Donors included 49 sibling donors (SIB), 48 matched
unrelated donors (MUD) and 15 mismatched unrelated donors
(mMUD). Median follow-up is 19.3 months (0 – 61.4) and the
Kaplan-Meier overall survival (OS) from NP visit is 77% at one
year and 56% at two years. Overall survival is not statistically differ-
ent between SIB, MUD or mMUD HCT (P5 0.39). In 58 pts who
did not receive a HCT, a donor was identified. (Yes donor, No
HCT) Median age was 57 yrs (19 – 69) with 28 pts older than
55yrs. At the NP visit, IPSS was Low (5), Int-1 (19), Int-2 (17),
High (16) and NE (1). Donors included SIB (14), MUD (27),
mMUD (15), and umbilical cord blood (2). Median follow up is
10.3 months (1.7 – 66.3). Seventy-three pts did not obtain a donor
(No Donor, No HCT). Median age was 64.4 yrs (32.6 – 72.1)
with 65 pts older than 55yrs. IPSS at NP visit was Low (8), Int-1
(16), Int-2 (25), High (16) and NE (8). Median follow up of these
pts is 6.7 months (0.9 – 61.3). For the entire cohort (243 pts), pts
with a donor had significantly improved overall survival vs pts with
no donor (P5 0.003); there was no difference in OS between pts
with a donor who did not proceed to HCT and everyone without
a donor (P5 0.27). Twenty-eight of the 73 pts without a donor
did not have donor searches. If these are excluded, in the remaining
215pts OS for pts with an identified donor was improved compared
to OS of those without a donor (P5 0.009) and pts with a donor and
no HCT had similar OS to those without an identified donor
(P5 0.3). These data demonstrate that 70% of patients can acquire
a suitable allogeneic donor and 47% of patients seen as a HCT new
